Biotech Values

[genisi]

Amgen's T-Vec in melanoma

advantage isn't as extreme as it first appears

Indeed, and from the inclusion/exclusion criteria, I don't see a big market for the treatment as monotherapy. Would be a lot bigger in the combo setting with Yervoy:

http://clinicaltrials.gov/ct2/show/NCT01740297?term=talimogene+laherparepvec&rank=1

Would be interesting to know if they found any effect on visceral metastases (as opposed to the injected lesions).